0001562180-22-007082.txt : 20221005
0001562180-22-007082.hdr.sgml : 20221005
20221005174023
ACCESSION NUMBER: 0001562180-22-007082
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221005
DATE AS OF CHANGE: 20221005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41477
FILM NUMBER: 221296616
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Ltd.
CENTRAL INDEX KEY: 0001935979
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
FORMER COMPANY:
FORMER CONFORMED NAME: Biohaven Research Ltd.
DATE OF NAME CHANGE: 20220629
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-10-03
false
0001935979
Biohaven Ltd.
BHVN
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN
CT
06510
false
false
true
false
Common Shares
2022-10-03
4
J
false
35839857.00
0.00
A
35839857.00
D
Common Shares
2022-10-03
4
J
false
35839857.00
0.00
D
0.00
D
On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance").
On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer.
/s/ George Clark, Attorney-in-Fact
2022-10-05